Matches in SemOpenAlex for { <https://semopenalex.org/work/W3139181937> ?p ?o ?g. }
- W3139181937 endingPage "1376" @default.
- W3139181937 startingPage "1376" @default.
- W3139181937 abstract "Muscle-invasive urothelial carcinoma (UC) is treated with cisplatin-based chemotherapy, which is only moderately efficient, mostly due to development of resistance. New therapy approaches are therefore urgently needed. Epigenetic alterations due to frequent mutations in epigenetic regulators contribute to development of the disease and to treatment resistance, and provide targets for novel drug combination therapies. Here, we determined the cytotoxic impact of the second-generation bromodomain protein inhibitor (BETi) PLX51107 on UC cell lines (UCC) and normal HBLAK control cells. PLX51107 inhibited proliferation, induced apoptosis, and acted synergistically with the histone deacetylase inhibitor romidepsin. While PLX51107 caused significant DNA damage, DNA damage signaling and DNA repair were impeded, a state defined as BRCAness. Accordingly, the drug strongly synergized with cisplatin more efficiently than romidepsin, and with the PARP inhibitor talazoparib to inhibit proliferation and induce cell death in UCC. Thus, a BETi can be used to “episensitize” UC cells to cytotoxic chemotherapy and inhibitors of DNA repair by inducing BRCAness in non BRCA1/2 mutated cancers. In clinical applications, the synergy between PLX51107 and other drugs should permit significant dosage reductions to minimize effects on normal tissues." @default.
- W3139181937 created "2021-03-29" @default.
- W3139181937 creator A5005704214 @default.
- W3139181937 creator A5009394334 @default.
- W3139181937 creator A5013194382 @default.
- W3139181937 creator A5024945919 @default.
- W3139181937 creator A5062139994 @default.
- W3139181937 creator A5077457020 @default.
- W3139181937 creator A5088518431 @default.
- W3139181937 date "2021-03-18" @default.
- W3139181937 modified "2023-10-05" @default.
- W3139181937 title "Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment" @default.
- W3139181937 cites W1577321276 @default.
- W3139181937 cites W1973462980 @default.
- W3139181937 cites W1974297564 @default.
- W3139181937 cites W1988838227 @default.
- W3139181937 cites W2038311942 @default.
- W3139181937 cites W2041535798 @default.
- W3139181937 cites W2061263553 @default.
- W3139181937 cites W2068523052 @default.
- W3139181937 cites W2082618949 @default.
- W3139181937 cites W2096439168 @default.
- W3139181937 cites W2100335940 @default.
- W3139181937 cites W2102971019 @default.
- W3139181937 cites W2103257412 @default.
- W3139181937 cites W2120572492 @default.
- W3139181937 cites W2137755195 @default.
- W3139181937 cites W2146729875 @default.
- W3139181937 cites W2168950900 @default.
- W3139181937 cites W2169287961 @default.
- W3139181937 cites W2174443766 @default.
- W3139181937 cites W2210685190 @default.
- W3139181937 cites W2230082983 @default.
- W3139181937 cites W2265659810 @default.
- W3139181937 cites W2272640380 @default.
- W3139181937 cites W2289591471 @default.
- W3139181937 cites W2411426401 @default.
- W3139181937 cites W2482220870 @default.
- W3139181937 cites W2534118209 @default.
- W3139181937 cites W2597062310 @default.
- W3139181937 cites W2601491802 @default.
- W3139181937 cites W2602446259 @default.
- W3139181937 cites W2737272162 @default.
- W3139181937 cites W2755838527 @default.
- W3139181937 cites W2770190286 @default.
- W3139181937 cites W2781495205 @default.
- W3139181937 cites W2784159027 @default.
- W3139181937 cites W2786719846 @default.
- W3139181937 cites W2789444905 @default.
- W3139181937 cites W2795208162 @default.
- W3139181937 cites W2800509387 @default.
- W3139181937 cites W2886726729 @default.
- W3139181937 cites W2893385575 @default.
- W3139181937 cites W2895926103 @default.
- W3139181937 cites W2900679912 @default.
- W3139181937 cites W2902946687 @default.
- W3139181937 cites W2921374955 @default.
- W3139181937 cites W2926397425 @default.
- W3139181937 cites W2944788711 @default.
- W3139181937 cites W2945696330 @default.
- W3139181937 cites W2950085917 @default.
- W3139181937 cites W29530928 @default.
- W3139181937 cites W2955452453 @default.
- W3139181937 cites W2965681656 @default.
- W3139181937 cites W2995898384 @default.
- W3139181937 cites W3000307305 @default.
- W3139181937 cites W3035853607 @default.
- W3139181937 cites W3039669474 @default.
- W3139181937 cites W3092300938 @default.
- W3139181937 cites W3110964033 @default.
- W3139181937 cites W3128905199 @default.
- W3139181937 doi "https://doi.org/10.3390/cancers13061376" @default.
- W3139181937 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8002916" @default.
- W3139181937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33803654" @default.
- W3139181937 hasPublicationYear "2021" @default.
- W3139181937 type Work @default.
- W3139181937 sameAs 3139181937 @default.
- W3139181937 citedByCount "4" @default.
- W3139181937 countsByYear W31391819372022 @default.
- W3139181937 countsByYear W31391819372023 @default.
- W3139181937 crossrefType "journal-article" @default.
- W3139181937 hasAuthorship W3139181937A5005704214 @default.
- W3139181937 hasAuthorship W3139181937A5009394334 @default.
- W3139181937 hasAuthorship W3139181937A5013194382 @default.
- W3139181937 hasAuthorship W3139181937A5024945919 @default.
- W3139181937 hasAuthorship W3139181937A5062139994 @default.
- W3139181937 hasAuthorship W3139181937A5077457020 @default.
- W3139181937 hasAuthorship W3139181937A5088518431 @default.
- W3139181937 hasBestOaLocation W31391819371 @default.
- W3139181937 hasConcept C104317684 @default.
- W3139181937 hasConcept C126322002 @default.
- W3139181937 hasConcept C134935766 @default.
- W3139181937 hasConcept C143425029 @default.
- W3139181937 hasConcept C154317977 @default.
- W3139181937 hasConcept C182979987 @default.
- W3139181937 hasConcept C190283241 @default.
- W3139181937 hasConcept C202751555 @default.
- W3139181937 hasConcept C2776202225 @default.